Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 15/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylformamide SCHEMBL27707831 | 0.89 | CPS1 (0.51) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL24338 | 0.85 | CPS1 (0.49) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL531399 | 0.83 | ALDH1A1 (0.65) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL1051747 | 0.83 | CPS1 (0.63) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL29639738 | 0.83 | ALDH1A1 (0.65) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL11197823 | 0.82 | NPC1 (0.55) | CPS1HPGDALDH1A1LMNANPC1 | |
| SCHEMBL312364 | 0.82 | KDM4E (0.51) | CPS1ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL72082 | 0.81 | CPS1 (0.61) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL15226106 | 0.81 | CPS1 (0.61) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL1554929 | 0.81 | CPS1 (0.61) | CPS1HPGDALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713306-A1 | NOVEL TRACER FOR THE IN VIVO DETECTION OF THE AGGREGATION OF ALPHA-SYNUCLEIN | Stichting Amsterdam UMC (NL) | 2026-03-25 | — | — | EP | disclosed |
| EP-4662209-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | Rezubio Pharmaceuticals Co., Ltd (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | disclosed |
| US-20250073338-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-03-06 | — | — | US | disclosed |
| WO-2024236054-A1 | NOVEL TRACER FOR THE IN VIVO DETECTION OF THE AGGREGATION OF ALPHA-SYNUCLEIN | Stichting Amsterdam UMC (NL) | 2024-11-21 | — | — | WO | disclosed |
| EP-4463451-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | Rezubio Pharmaceuticals Co., Ltd (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-118829638-A | Coupling compounds and compositions | 宁康瑞珠生物制药(珠海)有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118724796-A | Phenylpropionic acid derivative, and preparation method and application thereof | 广东众生睿创生物科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118619932-A | GPR40 agonist and preparation method and application thereof | 广东众生睿创生物科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-0833820-B1 | BENZISOXAZOLE AND INDAZOLE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | AVENTIS PHARMA INC (US) | 2001-02-14 | — | — | EP | disclosed |
| US-6166072-A | Amino acid derivatives | ALLELIX NEUROSCIENCE, INC. (CA) | 2000-12-26 | — | — | US | disclosed |
| US-6008348-A | TREATING A 1-TOSYLATED INDAZOL-3-YL PIPERAZINE DERIVATIVE WITH CONCENTRATED HYDROCHLORIC ACID TO PRODUCE THE DETOSYLATED INDAZOL-3-YL PIPERAZINE COMPOUND OF GIVEN FORMULA | HOECHST MARION ROUSSEL, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5965554-A | PIPERAZINYLBENZISOXAZOLE DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1999034790-A1 | GLYCINE TRANSPORT INHIBITORS | ALLELIX NEUROSCIENCE, INC. (US) | 1999-07-15 | — | — | WO | disclosed |
| US-5852022-A | Antipsychotic agents, composition and method of use | HOECHST ROUSSEL PHARMACEUTICALS INC. (US) | 1998-12-22 | — | — | US | disclosed |
| CN-1187192-A | Benzisoxazole and indazole derivatives as antipsychotic agents | HOECHST MARION ROUSSEL INC (US) | 1998-07-08 | — | — | CN | disclosed |
| EP-0833820-A1 | BENZISOXAZOLE AND INDAZOLE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | HOECHST MARION ROUSSEL, INC. (US) | 1998-04-08 | — | — | EP | disclosed |
| US-5696113-A | Antipsychotic agents, compositions and method of use | HOECHST MARION ROUSSEL, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1996039397-A1 | BENZISOXAZOLE AND INDAZOLE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | HOECHST MARION ROUSSEL, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | GPR119, GLP1R, GPR65 | CPS1 3641/4885HPGD 2699/4885ALDH1A1 2556/4885 |
| US-20250073338-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | GPR119, GPR65, GPR55 | CPS1 3778/4885HPGD 2084/4885ALDH1A1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.